Hot Investor Mandate: Life Sciences Platform Invests Up to $20M in Early-Stage Therapeutics, Diagnostics, and Medical Technologies

9 Jun

The firm is a life sciences accelerator, company creation platform, and investment organization founded in 2016 and based in the United States. As part of a broader healthcare investment ecosystem, the firm partners with scientists, entrepreneurs, and innovators to build and advance life sciences companies from early discovery through key clinical milestones. The firm provides capital, operational expertise, strategic guidance, and extensive industry relationships to accelerate the development of promising healthcare technologies. The firm typically makes Seed investments in the low single-digit millions and participates in larger Series A financings, while also syndicating opportunities alongside other investors. Through its broader investment network, portfolio companies may gain access to later-stage private, crossover, debt, and public market financing resources. The firm invests globally and supports companies from formation through clinical proof-of-concept and beyond.  

The firm invests broadly across life sciences and healthcare, including therapeutics, medical devices, diagnostics, and emerging healthcare technologies. The firm is modality-agnostic and evaluates a wide range of therapeutic approaches, including small molecules, biologics, peptides, antibodies, genetic medicines, cell therapies, and novel platform technologies. Beyond therapeutics, the firm is interested in diagnostics, medical technologies, digital health, telemedicine, artificial intelligence and machine learning-enabled healthcare solutions, and other enabling technologies that improve patient outcomes or healthcare delivery. The firm is generally disease-area agnostic and seeks innovative science addressing significant unmet medical needs.  

From a company and management team perspective, the firm is highly founder-friendly and open to working with a broad range of leadership teams, including first-time entrepreneurs and first-time CEOs. The firm takes a hands-on company-building approach, providing strategic, operational, scientific, and financing support throughout the company lifecycle. The firm typically prefers to lead investments and play an active role in company development while remaining open to syndicating opportunities alongside like-minded investors. The firm prioritizes strong science, differentiated technologies, and teams committed to building sustainable, high-impact healthcare companies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , , , ,

Hot Investor Mandate: Healthcare-Focused Investment Firm Deploys $10M Initial Checks in Seed to Series B Biopharmaceutical Companies

9 Jun

The firm is a healthcare-focused investment firm based in the United States with a long history of investing in innovative biotechnology and biopharmaceutical companies across both private and public markets. The firm manages dedicated private investment capital focused on emerging life sciences opportunities and typically invests from Seed through Series B financings. Initial investments often average approximately $10M, with substantial capacity for follow-on participation. Investments are primarily structured as equity, although convertible instruments may be utilized for select early-stage opportunities. The firm primarily invests in companies located in North America and Europe.  

The firm invests exclusively in therapeutics and biopharmaceutical innovation across a broad range of modalities and disease areas. The firm is modality-agnostic and evaluates opportunities involving small molecules, biologics, antibodies, RNA therapeutics, cell therapies, gene therapies, and other emerging therapeutic platforms. Areas of interest include oncology, immunology, rare diseases, metabolic disorders, and other indications characterized by significant unmet medical need. The firm prioritizes differentiated science, strong biological rationale, and technologies capable of generating meaningful clinical impact. The firm is comfortable investing from the preclinical stage onward and has experience supporting programs through major clinical development milestones.  

From a company and management team perspective, the firm seeks strong scientific founders, experienced leadership teams, and companies capable of advancing complex therapeutic programs through value-inflection points. The firm’s investment professionals bring deep scientific, medical, and financial expertise and work closely with portfolio companies as active strategic partners. The firm is open to leading, co-leading, or participating in investment syndicates and frequently assumes active governance roles, including board and observer positions. The firm provides support across financing strategy, clinical development planning, business development, and long-term company building. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , , ,

Hot Investor Mandate: European HealthTech VC Invests Up to €5M in Seed and Series A Companies with Commercial Traction

9 Jun

The firm is a European venture capital firm that invests in innovative healthcare and health technology companies addressing large global markets. Operating through a distributed team across multiple European countries, the firm primarily invests in European businesses. The firm typically participates in Seed and Series A financings and can invest up to approximately €5M per company over the life of an investment, including follow-on capital. The firm focuses on companies that have already demonstrated early commercial validation through initial revenues, customer adoption, or market traction. The firm takes an active role in helping portfolio companies scale internationally and build sustainable healthcare businesses.  

The firm focuses on healthcare and health technology companies with scalable business models and global market potential. While historically active across therapeutics, medical devices, diagnostics, and digital health, the firm now places greater emphasis on healthtech and B2B healthcare solutions. Key areas of interest include brain health, mental health, women’s health, digital therapeutics, healthcare software, diagnostics, patient engagement platforms, and technologies that improve the efficiency, accessibility, and delivery of healthcare. The firm generally favors companies with commercialized products, established customer demand, and clear pathways to scalable revenue growth.  

From a company and management team perspective, the firm seeks ambitious founders developing differentiated solutions to significant healthcare challenges. While the firm does not maintain strict requirements regarding management team composition or prior entrepreneurial experience, it places significant value on execution capability, market understanding, and international scaling potential. The firm works closely with portfolio companies following investment, providing strategic guidance, industry expertise, and access to a network of operators, investors, and commercial partners. The firm may act as either a lead investor or syndicate participant depending on the opportunity.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , ,

Hot Investor Mandate: Europe-Based VC Firm Invests € 1-3M in Technologies Addressing Diabetes and Chronic Disease Conditions 

9 Jun

The firm is a Europe-based venture capital firm with a dedicated investment strategy focused on diabetes and related disease areas. The firm primarily invests in Seed through Series A companies, with typical investments ranging from approximately €1-3M. The firm evaluates opportunities globally and is open to both leading and co-investing. Backed by a team with deep scientific expertise and extensive industry experience within the diabetes ecosystem, the firm takes an active role in supporting portfolio companies and frequently participates through board and observer positions.  

The firm focuses on diabetes and closely related indications, including comorbidities and complications where diabetes is a primary driver, such as kidney disease, wound care, vision loss, and other metabolic health challenges. The firm invests primarily in medical devices and digital health solutions, with a focus on both hardware and software technologies. Traditional biotechnology therapeutics fall outside the firm’s investment scope. For medical devices, the firm seeks opportunities that have progressed beyond the prototype stage and generated early validation data through laboratory studies, clinical evaluations, or first-in-human testing. For software and digital health solutions, the firm favors products demonstrating commercial traction or clear scalability. Strategic partnerships or demonstrated interest from healthcare providers, hospital systems, or established medical technology companies are viewed favorably, particularly for enterprise-focused solutions.  

From a company and management team perspective, the firm does not maintain specific requirements regarding founder or management team composition. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , ,

Don’t Miss Out: Discover Cutting-Edge Japanese Innovations at RESI San Diego 2026

9 Jun

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

With RESI San Diego 2026 just two weeks away, taking place on Monday, June 22, at JULEP Venue San Diego, we are excited to showcase a strong cohort of innovative life science companies and technologies from Japan.

As Title Sponsor of RESI San Diego 2026, Kobe Biomedical Innovation Cluster (KBIC) is organizing 2 incredible afternoon sessions featuring promising innovations that are being developed in Japan. We welcome you all to join and learn more about what Japan’s life science ecosystem has to offer.

Space is limited, so we ask that you RSVP to confirm your attendance.

RSVP to Confirm Attendance

1:00 – 3:00pm | KBIC Session –– Japan Life Science Showcase ––

KBIC is Japan’s largest leading biomedical cluster, bringing together approximately 350 companies, medical institutions, and research organizations.

Within this ecosystem, many startups are actively advancing R&D activities and working diligently toward commercialization on a daily basis.

As part of this exciting network, KBIC will host pitches from eight startups that are particularly eager to engage with overseas investors and licensing partners, and that are well prepared for such international collaboration.

In addition, leading venture capital firms in Japan and the representative of Ministry of Economy, Trade and Industry will speak about the current investment landscape as well as their perspectives on the future of the Japanese startup ecosystem.

ANT5 CellFold
FELIQS HIUCHI-Pharma
Juntendo-University Radio-Nano
United-Immunity VCCT

3:00 – 4:00pm | Kyoto-iCAP Session –– Translating Kyoto Science into Global Ventures ––

Kyoto University Innovation Capital Co., Ltd. (Kyoto-iCAP) and Kyoto University will introduce Kyoto’s growing biotech innovation ecosystem and showcase emerging life science ventures developing transformative technologies in regenerative medicine, cell therapy, nephrology, pain treatment and radiopharmaceuticals. The session is designed to foster connections between global investors, strategic partners, and leading Kyoto University-originated startups.

BTB Therapeutics CiRA
Orizuru-therapeutics Rege-Nephro
Shinobi_Therapeutics

Featured Interview: Dr. Narumiya, President of FBRI, shares his insights about Kobe and KBIC’s strengths and their role in strengthening the life science ecosystem in Japan.

Dr. Shuh Narumiya, President of Foundation for Biomedical Research and Innovation at Kobe (FBRI)

What is Kobe? What is KBIC?

Kobe is a port city and is now emerging as a key hub for startup creation and accumulation in Japan, particularly in bioscience and medicine. At the center of this ecosystem is the Kobe Biomedical Innovation Cluster (KBIC). In KBIC, you can meet institutes with Japan’s cutting-edge research, distinguished hospitals, research institutes of international Pharmas and start-ups, thus KBIC serving you as a “gateway to Japanese science and innovation”.

What science and innovation were and are being created in KBIC?

Science and innovation covered in KBIC span from drug discovery, regenerative medicine, digital health, and medical instruments and devices to bio-manufacturing. KBIC holds a distinctive position in regenerative medicine and cell therapy. It has, for example, nurtured and developed application of iPS cell research, leading to transplantation of iPSC-derived retinal cells in 2014, the world’s first clinical application, and the world’s first regulatory approval of iPSC-derived cells for a Parkinson’s disease treatment in 2026.

What are other advantages of KBIC?

Kobe is a part of Kansai region, an area of most distinguished life science research in Japan. Collaboration within the Kansai region is another strength of KBIC. Particularly, through partnerships with Kyoto University Innovation Capital (iCAP), KBIC supports the creation and growth of university spin-outs, combining Kyoto University’s research excellence with Kobe’s commercialization capabilities and vice versa.

What are the current state and issues of start-ups in Japan?

Today, Japan’s startup ecosystem—especially in the bio and life sciences sectors—is more vibrant than ever, producing a wealth of internationally competitive research and innovation seeds. However, these achievements are not yet fully recognized overseas, and many promising discoveries are still struggling for support to translate into commercial success. Bridging this gap is one of KBIC’s core roles.

Japan’s startups are now shifting from a domestically focused model to global expansion. In this transition, building international connections is critical. KBIC serves as a practical gateway for this purpose, offering integrated support from R&D to commercialization, fundraising, and global market entry.

Tags: , , , , , , , , , , , , , , , , ,

Discover the Innovators: 14 Pitch Sessions Showcasing Emerging Life Science Companies 

9 Jun

By Max Braht, VP of Business Development, LSN

Max-Braht-Headshot

The Innovator’s Pitch Challenge (IPC) returns to RESI San Diego with an exciting lineup of 14 pitch sessions showcasing emerging companies from across the life science ecosystem. Finalists represent a broad range of innovation spanning Therapeutics, Medical Devices, Diagnostics, and Digital Health, highlighting the technologies shaping the future of healthcare.

These sessions provide RESI attendees with a unique opportunity to discover breakthrough technologies and engage directly with the entrepreneurs driving them forward. Each company will present in front of a panel of active investors and strategic partners, participate in live Q&A discussions, and receive valuable feedback from industry experts.

In addition to presenting during their assigned pitch session, all IPC finalists will showcase their companies in the RESI exhibition area through dedicated pitch posters. This format allows attendees to explore innovative technologies at their own pace, connect directly with company leadership, and schedule follow-up discussions with promising startups throughout the conference.

The Innovator’s Pitch Challenge culminates with the presentation of RESI Cash awards, recognizing standout companies from across the competition. Award recipients will also be featured in Life Science Nation’s Next Phase newsletter, providing additional visibility among the global RESI community.

More than a competition, the Innovator’s Pitch Challenge serves as a platform for fundraising companies to gain visibility, validate their value proposition, and build meaningful relationships with investors, strategic partners, and industry leaders from around the world.

See the full list of pitching companies below:

Apply to Pitch at RESI Boston

Tags: , , , , , , , , , , , , ,

Don’t Underestimate the Importance of the Line 

9 Jun

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022

There is a line between deciding to pursue investors and partners and pursuing them. Most people believe they cross it the moment they decide. They don’t. Deciding is private. The line is the part the market can see, and the market only sees behavior. You can be completely certain you are committed and still be, as far as anyone outside your own head can tell, standing exactly where you were a year ago.

The market doesn’t care what you declare. It responds to what you do. What it reads is presence, whether you are in the room when it counts. There are moments when it counts more than others, when the people who fund and license and partner are not scattered across a thousand calendars but gathered in one place at one time, looking for their next opportunity. Those moments are real, and they are on the calendar. The wave forms whether you are ready or not. The only question it puts to you is whether you are in the water when it arrives.

Here is the part that surprises people. The companies that are serious about this do not try to be efficient about it. You would think the sophisticated move is to be selective, to take only the meetings that obviously matter and skip the rest. It isn’t, and there is a hard reason why. The meeting that changes your company does not announce itself going in. The lead investor is hidden inside a large number of conversations that look, beforehand, exactly like the ones that lead nowhere. The licensing partner is buried in a stack of introductions you cannot tell apart until you are sitting in them. You cannot reason your way to the one that counts and avoid the others. The only way to reach it is to go through the volume. So the serious company does not look for reasons to take fewer meetings. It looks for reasons to take more, because every additional relevant room is another draw from the deck the one card is hidden in. Most of the draws are blanks. That is not a flaw in the method. That is the method.

Activity guarantees nothing, and no one who has done this for long will tell you otherwise. What inactivity guarantees is the opposite. The company that is not in the room is not weighed, and ends up passed over. It is simply never seen, and the market does not hold a seat open for the company that didn’t show. It gives the seat to one that did. Which brings me to the week of June 22 in San Diego. That is a week the market gathers. The city fills with meetings, events, and venues all competing for the same hours, and RESI, on June 22, is built for exactly the thing I have been describing, a room assembled out of investors, licensing teams, and business development people who came specifically to find companies like yours.

Some of you reading this are already going to be there. You have a reason to be in San Diego that week, and you still have not decided to be in this particular room. Sit with that for a second. You will be in the same city, on the same days, with the market gathered a few miles away, and you are on the fence about walking in. There is a word for standing that close to the water, dressed to swim, watching the set roll past. The word is not caution. It is hesitation, and from the outside the market cannot tell the difference between a company that hesitated and a company that was never there.

The line we started with is not crossed by deciding you are ready. It is crossed in the open, by being where the market is while the market is there. If you believe you are ready, the week of June 22 is where that belief becomes visible or doesn’t. Register for RESI San Diego, June 22.

Don’t underestimate the importance of the line.

Register for RESI San Diego

Tags: , , , , , , , , , , , , , , , , , , , , ,

← Older Entries